Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent Partners with Synaffix to Create ADC Candidate from Antibody

publication date: Jun 29, 2021

Suzhou Innovent Bio signed a non-exclusive, target-specific license to use antibody-drug conjugate technology developed by Amsterdam's Synaffix. Synaffix will employ its programs to create an ADC candidate based on one of Innovent's antibodies. Synaffix will manufacture components that are specifically related to its proprietary technologies, but Innovent will be responsible for the rest of the product's development. Synaffix is eligible to receive upfront, potential milestone and royalty payments, though details were not disclosed. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.